var data={"title":"Rheumatoid nodules","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Rheumatoid nodules</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/contributors\" class=\"contributor contributor_credentials\">John M Davis, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/contributors\" class=\"contributor contributor_credentials\">James R O'Dell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/contributors\" class=\"contributor contributor_credentials\">Paul L Romain, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 08, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The rheumatoid nodule is the most common cutaneous manifestation of rheumatoid arthritis (RA) [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Although nodules commonly are found on pressure points (such as the olecranon process), they may occur at other sites, including ones within internal organs of the body. Thus, bedridden patients can develop nodules on the occiput and ischial areas, and nodules occasionally form on the Achilles tendon and vocal cords [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/3\" class=\"abstract_t\">3</a>]. Rheumatoid &quot;nodulosis&quot; is characterized by multiple nodules on the hands and multiple subchondral bone cysts known as &quot;geodes&quot; [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/4\" class=\"abstract_t\">4</a>]. These nodules tend to occur on extensor surfaces adjacent to joints, elbows, and fingers, as well as the forearm, metacarpophalangeal and proximal interphalangeal joints, occiput, back, heel, and other areas [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"abstract_t\">5</a>].</p><p>The clinical and histopathologic features, diagnosis, and treatment of rheumatoid nodules will be reviewed here. The articular features and an overview of the systemic and nonarticular manifestations of RA are presented separately. (See <a href=\"topic.htm?path=clinical-manifestations-of-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Clinical manifestations of rheumatoid arthritis&quot;</a> and <a href=\"topic.htm?path=overview-of-the-systemic-and-nonarticular-manifestations-of-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Overview of the systemic and nonarticular manifestations of rheumatoid arthritis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PREVALENCE AND CLINICAL SIGNIFICANCE</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Subcutaneous rheumatoid nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Palpable nodules in the subcutaneous tissues have been reported at initial presentation in 7 percent of patients with rheumatoid arthritis (RA) [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/6\" class=\"abstract_t\">6</a>] and are found at some time during the disease course in 30 to 40 percent of patients [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/7\" class=\"abstract_t\">7</a>]. In Rochester, Minnesota, the cumulative incidence of rheumatoid nodules remained unchanged between 1985 and 1994 and 1995 and 2007 at 31 percent [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/8\" class=\"abstract_t\">8</a>]. Further research is needed to determine the impact of evolving treatment strategies on the incidence of rheumatoid nodules in patients with early RA. The vast majority of nodule-formers have positive tests for rheumatoid factor [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/1\" class=\"abstract_t\">1</a>]. Nodules are found in 75 percent of patients with RA-associated Felty's syndrome [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-feltys-syndrome\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Felty's syndrome&quot;</a>.)</p><p>RA patients with nodules are also more likely to develop vasculitis [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/9\" class=\"abstract_t\">9</a>]. Limited data suggest that many patients with rheumatoid nodules have positive tests for antibodies to citrullinated proteins (ACPA) [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/10\" class=\"abstract_t\">10</a>]. In general, patients with rheumatoid nodules tend to have a severe RA phenotype, with more rapid progression of joint destruction than other patients with RA [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/11\" class=\"abstract_t\">11</a>]. Rheumatoid nodules have also been noted in occasional patients with systemic lupus erythematosus, ankylosing spondylitis, granuloma annulare, and chronic active hepatitis, and have been found infrequently in healthy children and adults [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"abstract_t\">5</a>]. An association of rheumatoid nodules in RA with the presence of antiphospholipid antibodies has also been reported [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/12\" class=\"abstract_t\">12</a>]. Patients with rheumatoid nodules are also at greater risk of hospitalization [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/13\" class=\"abstract_t\">13</a>] due to complications of their disease or comorbidities and to experience lower extremity ulcers, which are associated with significant morbidity related to soft tissue, bone, and joint infections [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/14\" class=\"abstract_t\">14</a>].</p><p>The size of the nodules varies from 2 mm to 5 cm; they are firm, nontender, and moveable in subcutaneous tissue (<a href=\"image.htm?imageKey=DERM%2F74194\" class=\"graphic graphic_picture graphicRef74194 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"abstract_t\">5</a>].</p><p>In many cases, the nodules are neither symptomatic nor a cosmetic concern. However, rheumatoid nodules can be painful <span class=\"nowrap\">and/or</span> disfiguring, can interfere with function, and can cause compressive neuropathies. Some patients find the nodules more distressing than the arthritis. The nodules may also ulcerate and thus serve as a site for local infection or other distant infectious complications by hematogenous spread of bacteria.</p><p>A poorly understood phenomenon is that some patients treated for RA with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> have a noticeable increase in the size and number of rheumatoid nodules. This is referred to as accelerated nodulosis (see <a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate#H59546661\" class=\"medical medical_review\">&quot;Major side effects of low-dose methotrexate&quot;, section on 'Nodulosis'</a>). Typically, patients with this condition rapidly develop numerous small subcutaneous nodules primarily over the fingers, hands, or wrists, though other sites have been described, such as elbows, scalp, Achilles tendon, larynx, and lungs [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/15,16\" class=\"abstract_t\">15,16</a>]. The onset of methotrexate-induced accelerated nodulosis may occur as early as one month and as long as eight years after the initiation of methotrexate therapy [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Nodulosis has also occasionally been associated in RA patients with treatment with <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, and <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a> [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"abstract_t\">5</a>]. Nodules associated with methotrexate therapy are otherwise similar in their morphology and clinical manifestations to usual RA nodules.</p><p>The presence of subcutaneous rheumatoid nodules is predictive of increased risk of cardiovascular disease as well as cardiovascular, respiratory, and all-cause mortality [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Identification of nodules should particularly alert clinicians to the heightened cardiovascular risk and the need for careful assessment and modification of cardiovascular risk factors. (See <a href=\"topic.htm?path=coronary-artery-disease-in-rheumatoid-arthritis-implications-for-prevention-and-management\" class=\"medical medical_review\">&quot;Coronary artery disease in rheumatoid arthritis: Implications for prevention and management&quot;</a> and <a href=\"topic.htm?path=cardiovascular-disease-risk-assessment-for-primary-prevention-our-approach\" class=\"medical medical_review\">&quot;Cardiovascular disease risk assessment for primary prevention: Our approach&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Pulmonary nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of pulmonary rheumatoid nodules in patients with RA depends in part on the methods used for detection. As an example, plain film radiographs of the chest revealed rheumatoid nodules in only 2 of 516 patients with RA in one clinical series [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/19\" class=\"abstract_t\">19</a>]. However, a study of open lung biopsies from 40 patients with suspected lung disease found rheumatoid nodules in 13 subjects (32 percent); in 8 of 13 patients, there were multiple nodules [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/20\" class=\"abstract_t\">20</a>]. Accelerated pulmonary nodulosis has been reported to follow <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, anti-tumor necrosis factor (TNF) therapy, and <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a> treatment [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/21-24\" class=\"abstract_t\">21-24</a>]. These can mimic infection or malignancy.</p><p>Nodules are generally located in subpleural areas or in association with interlobular septa [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/25\" class=\"abstract_t\">25</a>]. Pulmonary rheumatoid nodules are generally asymptomatic but can lead to complications including pleural effusion, pneumothorax, pyopneumothorax, bronchopleural fistula, and hemoptysis. These and other aspects of rheumatoid nodules in the lungs are discussed in more detail elsewhere. (See <a href=\"topic.htm?path=overview-of-lung-disease-associated-with-rheumatoid-arthritis#H16\" class=\"medical medical_review\">&quot;Overview of lung disease associated with rheumatoid arthritis&quot;, section on 'Rheumatoid lung nodules'</a>.)</p><p>Lymphoid aggregates containing B lymphocytes and features characteristic of lymphoid follicles have been reported in pulmonary nodules [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/26\" class=\"abstract_t\">26</a>]. This contrasts with the expected structure of subcutaneous nodules, from which B cells and lymphoid follicles are normally absent. Such B cell aggregates may also occur in diffuse RA-associated interstitial lung disease, such as nonspecific interstitial pneumonitis or usual interstitial pneumonitis [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Consistent with these histopathologic features, reduction in size or even disappearance of pulmonary rheumatoid nodules may sometimes be seen in patients with severe RA treated with the B-cell-depleting agent <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Cardiac nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rheumatoid nodules may develop in the pericardium, myocardium, and valvular structures [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/29\" class=\"abstract_t\">29</a>]. They may be noted on echocardiograms [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/30\" class=\"abstract_t\">30</a>]. Symptoms related to the presence of nodules are rare, but syncope or death due to heart block from a lesion situated in the conduction system can occur [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/31\" class=\"abstract_t\">31</a>]. Stroke or other manifestations of arterial embolization may result from nodules on a heart valve [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/32-34\" class=\"abstract_t\">32-34</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Central nervous system nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rheumatoid nodules rarely may affect the central nervous system. This is discussed in detail elsewhere. (See <a href=\"topic.htm?path=neurologic-manifestations-of-rheumatoid-arthritis#H8\" class=\"medical medical_review\">&quot;Neurologic manifestations of rheumatoid arthritis&quot;, section on 'Rheumatoid nodules'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">PATHOLOGY AND PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histologic appearance of a typical rheumatoid nodule includes a central area of necrosis surrounded in turn by palisading macrophages and then lymphocytes (<a href=\"image.htm?imageKey=RHEUM%2F69272\" class=\"graphic graphic_picture graphicRef69272 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/35-38\" class=\"abstract_t\">35-38</a>]. The fibroblasts produce large quantities of metalloproteases [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/39\" class=\"abstract_t\">39</a>]. The lymphocytes can generate IgG and IgM rheumatoid factor. Histologic features of focal vasculitis with associated immunoglobulin, fibrin deposition, and complement activation can be found in one-third of all rheumatoid nodules [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Examination for mRNA transcripts for cytokines revealed evidence for tumor necrosis factor (TNF) alpha, interferon gamma, interleukin (IL)-1 beta, IL-1 receptor antagonist, IL-10, IL-15, IL-18, and IL-12 (but not IL-2 or IL-4), as well as adhesion molecules E-selectin, intracellular adhesion molecule (ICAM)-1, platelet endothelial cell adhesion molecule (PECAM), and vascular cell adhesion molecule (VCAM). IL-17A is not found in rheumatoid nodules, in contrast to its presence in the rheumatoid synovial membrane [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/40\" class=\"abstract_t\">40</a>], but most of the cytokine profile, together with the ability of the tissue to produce metalloproteinases, establishes the rheumatoid nodule as a Th1 granuloma [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/41-43\" class=\"abstract_t\">41-43</a>]. (See <a href=\"topic.htm?path=role-of-cytokines-in-rheumatic-diseases\" class=\"medical medical_review\">&quot;Role of cytokines in rheumatic diseases&quot;</a>.)</p><p>Deposits of rheumatoid factor and the terminal components of complement are also found on the endothelium of small vessels within nodules [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/44\" class=\"abstract_t\">44</a>]. A meta-analysis of individual patient data from published studies showed no strong association between the presence of nodules and carriage of major histocompatibility complex (MHC) alleles (shared epitope) that are associated with rheumatoid arthritis (RA) per se. There was a very weak association with only the human leukocyte antigen (HLA)DRbeta1*0401 shared epitope allele but not with other genotypes [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/45\" class=\"abstract_t\">45</a>]. This contrasts with a similar analysis of studies of RA-associated vasculitis, in which an association between vasculitis and a double dose of the shared epitope was found [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/46\" class=\"abstract_t\">46</a>], suggesting that HLA alleles may be less important for development of nodules than for other extraarticular disease features. (See <a href=\"topic.htm?path=hla-and-other-susceptibility-genes-in-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;HLA and other susceptibility genes in rheumatoid arthritis&quot;</a>.)</p><p>In contrast to the very weak association with HLA, IL-4 receptor (<em>IL4R</em>) single-nucleotide polymorphisms are associated with rheumatoid nodules. In a sample of 749 patients in the Consortium for Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) registry, the presence of <em>IL4R</em> single-nucleotide polymorphisms, either rs1801275 (odds ratio 8.1, 95% CI 1.6-40.9) or rs1805010 (odds ratio 2.74, 95% CI 0.80 to 9.41), was associated with the presence of rheumatoid nodules in patients with at least one HLA-DRB1 allele encoding the shared epitope [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/47\" class=\"abstract_t\">47</a>]. The mechanism is unknown, but diminished responsiveness to IL-4 signaling could contribute to Th1-mediated inflammation.</p><p>As noted above, a complication of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> therapy in some patients with RA is the increased formation of rheumatoid nodules, a proinflammatory effect that occurs even when synovial inflammation is suppressed [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/48\" class=\"abstract_t\">48</a>]. Among susceptible individuals, this complication may be due to the activation of adenosine A1 receptors by methotrexate, which leads to enhanced cellular fusion and the formation of multinucleated giant cells [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate#H59546661\" class=\"medical medical_review\">&quot;Major side effects of low-dose methotrexate&quot;, section on 'Nodulosis'</a>.)</p><p>Cigarette smoking may increase the risk of developing rheumatoid nodules. This was illustrated in a study of 1589 patients with early RA in which those with nodules were compared with age- and sex-matched RA controls [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/6\" class=\"abstract_t\">6</a>]. Those with nodules were significantly more likely to have ever smoked cigarettes (odds ratio 7.3, 95% CI 2.3-24.6). Smoking is also associated with vasculitis [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/50,51\" class=\"abstract_t\">50,51</a>] and other severe extraarticular manifestations of RA [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/52,53\" class=\"abstract_t\">52,53</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In a patient with rheumatoid arthritis (RA), a slowly developing, firm, painless, subcutaneous nodule located at a pressure point is almost certainly a rheumatoid nodule. These can be movable or bound down to underlying fascia or periosteum. In the absence of symptoms related to the presence of the nodule, no additional diagnostic testing is necessary. Indications for biopsy include progressive rapid growth, unusual location, ulceration, or a suspected alternative diagnosis such as infection or malignancy.</p><p>Rheumatoid nodules in viscera may be more difficult to diagnose with confidence. As an example, a rheumatoid nodule in the lung may not be definitively diagnosed until lung cancer has been excluded by biopsy or excision. (See <a href=\"topic.htm?path=overview-of-lung-disease-associated-with-rheumatoid-arthritis#H16\" class=\"medical medical_review\">&quot;Overview of lung disease associated with rheumatoid arthritis&quot;, section on 'Rheumatoid lung nodules'</a>.)</p><p>The finding of a nodule with the histologic characteristics described above for rheumatoid nodules (see <a href=\"#H7\" class=\"local\">'Pathology and pathogenesis'</a> above) is nearly pathognomonic of RA. However, nodules with a similar histologic appearance rarely occur in some patients with systemic lupus erythematosus and in otherwise healthy children [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/54-58\" class=\"abstract_t\">54-58</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Differential diagnosis</span></p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Subcutaneous nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of subcutaneous rheumatoid nodules should include fibromas caused by chronic trauma from shoes or repetitive use of hand tools, subcutaneous granuloma annulare (pseudo rheumatoid nodules), xanthomatosis, sarcoidosis, gouty tophi, pseudogout tophi [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/59\" class=\"abstract_t\">59</a>], cutaneous extravascular necrotizing granulomas (historically termed &ldquo;Churg-Strauss granulomas&rdquo;), tumoral calcinosis, fibromas unrelated to chronic trauma, xanthomas, subcutaneous sarcoidosis, lupus panniculitis, nodular (keloidal) scleroderma, metastatic tumors, histoplasmosis, amyloidosis, ganglion cysts, foreign body granulomas, basal cell skin cancer, epidermoid cysts, synovial cysts, necrobiotic granulomas, and necrobiosis lipoidica [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/1,5\" class=\"abstract_t\">1,5</a>]. However, the concurrent presence of active RA with high rheumatoid factor titers points strongly toward rheumatoid nodules.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Lung nodule or nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As noted above, the most important diagnosis to exclude in a patient with RA and a pulmonary nodule is non-small cell lung cancer at a potentially curable stage. The approach to a patient with RA and an asymptomatic pulmonary nodule is similar to that for others with solitary nodules. If radiographic stability of the lesion cannot be demonstrated conclusively by review of prior chest radiographs, or if prior studies are unavailable, then consideration can be given to additional investigations; these include continued observation with serial imaging studies, biopsy of the lesion, and surgical excision. An approach to diagnosis of a solitary pulmonary nodule is presented separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">&quot;Diagnostic evaluation of the incidental pulmonary nodule&quot;</a>.)</p><p>Rheumatoid nodulosis is one of several benign and malignant diseases that are associated with the presence of multiple pulmonary nodules. A discussion of the causes of multiple pulmonary nodules and an approach to diagnosis are presented separately. (See <a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">&quot;Differential diagnosis and evaluation of multiple pulmonary nodules&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Accelerated nodulosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If the formation of rheumatoid nodules is suspected to be due to use of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, discontinuing treatment with this agent can be considered. A decision to stop or continue methotrexate therapy depends on several factors, including the success with which rheumatoid arthritis (RA) disease activity other than nodulosis has been controlled by methotrexate, the availability of other disease-modifying antirheumatic drugs (DMARDs) and biologic response modifying agents (eg, anti-tumor necrosis factor [TNF] alpha agents), safety of alternative drugs, and cost concerns. Discontinuation of methotrexate and a change to an alternative DMARD or biologic response modifier may be appropriate, while some patients and their clinicians may decide to continue methotrexate. Nodules commonly require six months (range, 1 to 13 months) to regress after discontinuation of methotrexate [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/16\" class=\"abstract_t\">16</a>]. Based on a review of case reports, approximately 70 percent of cases of accelerated nodulosis resolve with stopping the methotrexate [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Regression of nodules has also been noted in patients who received various other DMARDs or <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">colchicine</a>; however, a review in 2002 found insufficient evidence to conclude that any specific treatment was beneficial for methotrexate-associated nodulosis [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/15\" class=\"abstract_t\">15</a>]. Subsequent case reports suggest that <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a> may be effective treatment for some cases of severe subcutaneous nodulosis [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/60\" class=\"abstract_t\">60</a>], and that rituximab and <a href=\"topic.htm?path=tocilizumab-drug-information\" class=\"drug drug_general\">tocilizumab</a> can cause regression of pulmonary rheumatoid nodules [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/61,62\" class=\"abstract_t\">61,62</a>].</p><p>For patients with symptomatic accelerated nodulosis in the setting of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> treatment, for whom there are viable alternative treatments, we suggest the discontinuation of methotrexate and a change to an alternative DMARD or biologic response modifier. Patients whose articular disease activity is well-controlled and whose nodulosis is only a cosmetic concern may choose to continue methotrexate therapy.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Subcutaneous nodules</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Asymptomatic nodules require no specific treatment. However, those that are painful, interfere with function, or cause nerve entrapment may require an intervention. Direct injection of the nodule with a mixture of glucocorticoids and local anesthetic may be beneficial and is recommended. Surgical excision may be necessary for nodules that are causing serious complications. One patient without RA, but with nodules consistent with rheumatoid nodulosis on biopsy, has been reported to respond to topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> after failing to respond to topical corticosteroids [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Glucocorticoid injection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Local glucocorticoid injection of rheumatoid nodules is often effective in decreasing their size. This was illustrated in a study of 24 nodules in 11 patients with RA. Patients were randomly assigned for each injection to receive either <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> or placebo, and assessment was blinded [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/64\" class=\"abstract_t\">64</a>]. A &gt;50 percent loss in nodule volume occurred in a significantly greater proportion of those who received glucocorticoid injections when compared with placebo injections (9 of 12 versus 1 of 12, respectively). Similar findings were later reported in a study of 20 patients (one nodule each) of comparable design, but, instead of methylprednisolone, <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> hexacetonide was injected and was found to be superior to placebo [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/65\" class=\"abstract_t\">65</a>].</p><p>A long-acting glucocorticoid (eg, 0.1 to 0.3 mL of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> or <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> hexacetonide 40 <span class=\"nowrap\">mg/mL)</span> and local anesthetic (eg, 1 percent <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>) in a 1:1 mixture by volume are typically used for injection. (See <a href=\"topic.htm?path=intraarticular-and-soft-tissue-injections-what-agents-to-inject-and-how-frequently\" class=\"medical medical_review\">&quot;Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Surgical excision</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Indications for surgical treatment of rheumatoid nodules include skin erosion and infection, pain or neurologic dysfunction arising from pressure on a peripheral nerve, and limitation of motion because of the location of the lesion [<a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/58\" class=\"abstract_t\">58</a>]. Recurrence of nodules at the same site is frequently seen.</p><p>As noted (see <a href=\"#H11\" class=\"local\">'Lung nodule or nodules'</a> above), surgical resection of pulmonary nodules is sometimes indicated. Surgical or intravascular approaches to cardiac nodules should be undertaken only when there is firm evidence that the nodules are contributing to abnormal cardiac function, to rhythm disturbances, or to embolic events.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rheumatoid nodules are a common extra-articular manifestation of rheumatoid arthritis (RA), with subcutaneous nodules occurring at some time in 30 to 40 percent of patients. (See <a href=\"#H3\" class=\"local\">'Subcutaneous rheumatoid nodules'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with rheumatoid nodules have greater incidence of severe disease phenotypes, including propensity for joint destruction, development of other extraarticular manifestations, and increased cardiovascular, pulmonary, and all-cause mortality. (See <a href=\"#H3\" class=\"local\">'Subcutaneous rheumatoid nodules'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wherever rheumatoid nodules are found, they have a similar histologic appearance. Characteristic features include a central area of necrosis surrounded by concentric layers of palisading macrophages and lymphocytes. As is the case for the synovitis of RA, the pathogenesis is uncertain but involves multiple cytokines. (See <a href=\"#H7\" class=\"local\">'Pathology and pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of subcutaneous lesions can be made from their proximity to pressure points, generally intact overlying skin, and firm to hard nature on palpation, often with fixation to the underlying periosteum. Although the histopathologic features are nearly pathognomonic, biopsy is rarely necessary for diagnosis of rheumatoid nodules located in or beneath the skin. (See <a href=\"#H8\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rheumatoid pulmonary nodules present a more difficult diagnostic challenge. When an asymptomatic single lung nodule is discovered, we recommend a thorough evaluation to exclude a potentially resectable lung cancer. An approach to diagnosis in this setting is discussed in more detail elsewhere. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">&quot;Diagnostic evaluation of the incidental pulmonary nodule&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rheumatoid nodules in the myocardium can cause heart block; lesions located on or near the heart valves may cause regurgitation or embolic events. (See <a href=\"#H5\" class=\"local\">'Cardiac nodules'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The presence of multiple pulmonary nodules requires thorough evaluation to exclude treatable infectious and potentially curable neoplastic diseases. The differential diagnosis and evaluation of such patients is presented separately. (See <a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">&quot;Differential diagnosis and evaluation of multiple pulmonary nodules&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For an asymptomatic subcutaneous nodule, targeted therapy is not necessary. For symptomatic nodules, we recommend local injection of glucocorticoids and a local anesthetic as the initial treatment (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H15\" class=\"local\">'Glucocorticoid injection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A complication of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> therapy in some patients with RA is the increased formation of rheumatoid nodules. In patients for whom there are viable alternative treatments, we suggest discontinuation of methotrexate and a change to an alternative disease-modifying antirheumatic drug (DMARD) or biologic response modifier (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Patients whose articular disease activity is well-controlled and whose nodulosis is only a cosmetic concern may choose to continue methotrexate therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with symptomatic subcutaneous nodules that have resulted in complications (eg, skin ulceration, nerve compression) and that either are not appropriate for steroid injection or have not responded to local injection, surgical excision may be necessary. (See <a href=\"#H16\" class=\"local\">'Surgical excision'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/1\" class=\"nounderline abstract_t\">Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53:191.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/2\" class=\"nounderline abstract_t\">Highton J, Hessian PA, Stamp L. The Rheumatoid nodule: peripheral or central to rheumatoid arthritis? Rheumatology (Oxford) 2007; 46:1385.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/3\" class=\"nounderline abstract_t\">Ylitalo R, Heimb&uuml;rger M, Lindestad PA. Vocal fold deposits in autoimmune disease--an unusual cause of hoarseness. Clin Otolaryngol Allied Sci 2003; 28:446.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/4\" class=\"nounderline abstract_t\">Ginsberg MH, Genant HK, Y&uuml; TF, McCarty DJ. Rheumatoid nodulosis: an unusual variant of rheumatoid disease. Arthritis Rheum 1975; 18:49.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/5\" class=\"nounderline abstract_t\">Garc&iacute;a-Patos V. Rheumatoid nodule. Semin Cutan Med Surg 2007; 26:100.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/6\" class=\"nounderline abstract_t\">Nyh&auml;ll-W&aring;hlin BM, Jacobsson LT, Petersson IF, et al. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 2006; 65:601.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/7\" class=\"nounderline abstract_t\">Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33:65.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/8\" class=\"nounderline abstract_t\">Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38:983.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/9\" class=\"nounderline abstract_t\">Turesson C, McClelland RL, Christianson T, Matteson E. Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol 2008; 35:179.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/10\" class=\"nounderline abstract_t\">Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J Rheumatol 2008; 35:995.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/11\" class=\"nounderline abstract_t\">Nyh&auml;ll-W&aring;hlin BM, Turesson C, Jacobsson LT, et al. The presence of rheumatoid nodules at early rheumatoid arthritis diagnosis is a sign of extra-articular disease and predicts radiographic progression of joint destruction over 5 years. Scand J Rheumatol 2011; 40:81.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/12\" class=\"nounderline abstract_t\">Wolf P, Gretler J, Aglas F, et al. Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol 1994; 131:48.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/13\" class=\"nounderline abstract_t\">Michet CJ 3rd, Strobova K, Achenbach S, et al. Hospitalization rates and utilization among patients with rheumatoid arthritis: a population-based study from 1987 to 2012 in Olmsted County, Minnesota. Mayo Clin Proc 2015; 90:176.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/14\" class=\"nounderline abstract_t\">Jebakumar AJ, Udayakumar PD, Crowson CS, et al. Occurrence and effect of lower extremity ulcer in rheumatoid arthritis -- a population-based Study. J Rheumatol 2014; 41:437.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/15\" class=\"nounderline abstract_t\">Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 2002; 22:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/16\" class=\"nounderline abstract_t\">Ahmed SS, Arnett FC, Smith CA, et al. The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. Medicine (Baltimore) 2001; 80:271.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/17\" class=\"nounderline abstract_t\">Kaushik P, Solomon DH, Greenberg JD, et al. Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry. Clin Rheumatol 2015; 34:1697.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/18\" class=\"nounderline abstract_t\">England BR, Sayles H, Michaud K, et al. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2016; 68:36.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/19\" class=\"nounderline abstract_t\">Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968; 47:501.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/20\" class=\"nounderline abstract_t\">Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985; 131:770.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/21\" class=\"nounderline abstract_t\">Watson P, Simler N, Screaton N, Lillicrap M. Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:928.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/22\" class=\"nounderline abstract_t\">Horvath IF, Szanto A, Csiki Z, et al. Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. Pathol Oncol Res 2008; 14:101.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/23\" class=\"nounderline abstract_t\">Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006; 25:384.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/24\" class=\"nounderline abstract_t\">Akiyama N, Toyoshima M, Kono M, et al. Methotrexate-induced Accelerated Pulmonary Nodulosis. Am J Respir Crit Care Med 2015; 192:252.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/25\" class=\"nounderline abstract_t\">Walters MN, Ojeda VJ. Pleuropulmonary necrobiotic rheumatoid nodules. A review and clinicopathological study of six patients. Med J Aust 1986; 144:648.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/26\" class=\"nounderline abstract_t\">Highton J, Hung N, Hessian P, Wilsher M. Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology (Oxford) 2007; 46:811.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/27\" class=\"nounderline abstract_t\">Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006; 54:635.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/28\" class=\"nounderline abstract_t\">Glace B, Gottenberg JE, Mariette X, et al. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Ann Rheum Dis 2012; 71:1429.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/29\" class=\"nounderline abstract_t\">Kitas G, Banks MJ, Bacon PA. Cardiac involvement in rheumatoid disease. Clin Med (Lond) 2001; 1:18.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/30\" class=\"nounderline abstract_t\">Wis&#322;owska M, Sypu&#322;a S, Kowalik I. Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int 1999; 18:163.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/31\" class=\"nounderline abstract_t\">Ahern M, Lever JV, Cosh J. Complete heart block in rheumatoid arthritis. Ann Rheum Dis 1983; 42:389.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/32\" class=\"nounderline abstract_t\">Chatzis A, Giannopoulos N, Baharakakis S, et al. Unusual cause of a stroke in a patient with seronegative rheumatoid arthritis. Cardiovasc Surg 1999; 7:659.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/33\" class=\"nounderline abstract_t\">Mounet FS, Soula P, Concina P, Cerene A. A rare case of embolizing cardiac tumor: rheumatoid nodule of the mitral valve. J Heart Valve Dis 1997; 6:77.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/34\" class=\"nounderline abstract_t\">Kang H, Baron M. Embolic complications of a mitral valve rheumatoid nodule. J Rheumatol 2004; 31:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/35\" class=\"nounderline abstract_t\">Palmer DG, Hogg N, Highton J, et al. Macrophage migration and maturation within rheumatoid nodules. Arthritis Rheum 1987; 30:728.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/36\" class=\"nounderline abstract_t\">Athanasou NA, Quinn J, Woods CG, Mcgee JO. Immunohistology of rheumatoid nodules and rheumatoid synovium. Ann Rheum Dis 1988; 47:398.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/37\" class=\"nounderline abstract_t\">Miyasaka N, Sato K, Yamamoto K, et al. Immunological and immunohistochemical analysis of rheumatoid nodules. Ann Rheum Dis 1989; 48:220.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/38\" class=\"nounderline abstract_t\">Wikaningrum R, Highton J, Parker A, et al. Pathogenic mechanisms in the rheumatoid nodule: comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum 1998; 41:1783.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/39\" class=\"nounderline abstract_t\">Harris ED Jr. A collagenolytic system produced by primary cultures of rheumatoid nodule tissue. J Clin Invest 1972; 51:2973.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/40\" class=\"nounderline abstract_t\">Stamp LK, Easson A, Lehnigk U, et al. Different T cell subsets in the nodule and synovial membrane: absence of interleukin-17A in rheumatoid nodules. Arthritis Rheum 2008; 58:1601.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/41\" class=\"nounderline abstract_t\">Hessian PA, Highton J, Kean A, et al. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 2003; 48:334.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/42\" class=\"nounderline abstract_t\">Edwards JC, Wilkinson LS, Pitsillides AA. Palisading cells of rheumatoid nodules: comparison with synovial intimal cells. Ann Rheum Dis 1993; 52:801.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/43\" class=\"nounderline abstract_t\">Elewaut D, De Keyser F, De Wever N, et al. A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis 1998; 57:480.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/44\" class=\"nounderline abstract_t\">Kato H, Yamakawa M, Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol 2000; 27:1839.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/45\" class=\"nounderline abstract_t\">Gorman JD, David-Vaudey E, Pai M, et al. Lack of association of the HLA-DRB1 shared epitope with rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis. Arthritis Rheum 2004; 50:753.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/46\" class=\"nounderline abstract_t\">Gorman JD, David-Vaudey E, Pai M, et al. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004; 50:3476.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/47\" class=\"nounderline abstract_t\">Burgos PI, Causey ZL, Tamhane A, et al. Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. Arthritis Res Ther 2010; 12:R75.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/48\" class=\"nounderline abstract_t\">Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991; 88:2441.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/49\" class=\"nounderline abstract_t\">Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 1997; 40:1308.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/50\" class=\"nounderline abstract_t\">Struthers GR, Scott DL, Delamere JP, et al. Smoking and rheumatoid vasculitis. Rheumatol Int 1981; 1:145.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/51\" class=\"nounderline abstract_t\">Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2776.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/52\" class=\"nounderline abstract_t\">Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62:722.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/53\" class=\"nounderline abstract_t\">Nyh&auml;ll-W&aring;hlin BM, Petersson IF, Nilsson JA, et al. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:416.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/54\" class=\"nounderline abstract_t\">Schofield JK, Cerio R, Grice K. Systemic lupus erythematosus presenting with 'rheumatoid nodules'. Clin Exp Dermatol 1992; 17:53.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/55\" class=\"nounderline abstract_t\">Hassikou H, Le Guilchard F, Lespessailles E, et al. Rheumatoid nodules in systemic lupus erythematosus: a case report. Joint Bone Spine 2003; 70:234.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/56\" class=\"nounderline abstract_t\">Simons FE, Schaller JG. Benign rheumatoid nodules. Pediatrics 1975; 56:29.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/57\" class=\"nounderline abstract_t\">Mastboom WJ, van der Staak FH, Festen C, Postma MH. Subcutaneous rheumatoid nodules. Arch Dis Child 1988; 63:662.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/58\" class=\"nounderline abstract_t\">McGrath MH, Fleischer A. The subcutaneous rheumatoid nodule. Hand Clin 1989; 5:127.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/59\" class=\"nounderline abstract_t\">Sander O, Scherer A. Mimicry of a rheumatoid nodule by tophaceous pseudogout at the elbow. J Rheumatol 2008; 35:1419.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/60\" class=\"nounderline abstract_t\">Sautner J, Rintelen B, Leeb BF. Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52:1535.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/61\" class=\"nounderline abstract_t\">De Stefano R, Frati E, Nargi F, Menza L. Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-&#61472;&alpha; therapy. Clin Exp Rheumatol 2011; 29:752.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/62\" class=\"nounderline abstract_t\">Andres M, Vela P, Romera C. Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. Rheumatology (Oxford) 2012; 51:1132.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/63\" class=\"nounderline abstract_t\">Garrido-R&iacute;os A, S&aacute;nchez-Velicia L, Sanz-Mu&ntilde;oz C, et al. Rheumatoid nodulosis: successful response to topical tacrolimus. Clin Rheumatol 2009; 28:1341.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/64\" class=\"nounderline abstract_t\">Ching DW, Petrie JP, Klemp P, Jones JG. Injection therapy of superficial rheumatoid nodules. Br J Rheumatol 1992; 31:775.</a></li><li><a href=\"https://www.uptodate.com/contents/rheumatoid-nodules/abstract/65\" class=\"nounderline abstract_t\">Baan H, Haagsma CJ, van de Laar MA. Corticosteroid injections reduce size of rheumatoid nodules. Clin Rheumatol 2006; 25:21.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7523 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PREVALENCE AND CLINICAL SIGNIFICANCE</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Subcutaneous rheumatoid nodules</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Pulmonary nodules</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Cardiac nodules</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Central nervous system nodules</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">PATHOLOGY AND PATHOGENESIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIAGNOSIS</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Differential diagnosis</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Subcutaneous nodules</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Lung nodule or nodules</a></li></ul></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">TREATMENT</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Accelerated nodulosis</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Subcutaneous nodules</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">- Glucocorticoid injection</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Surgical excision</a></li></ul></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"RHEUM/7523|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/74194\" class=\"graphic graphic_picture\">- Rheumatoid nodules</a></li><li><a href=\"image.htm?imageKey=RHEUM/69272\" class=\"graphic graphic_picture\">- Rheumatoid nodule Low</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cardiovascular-disease-risk-assessment-for-primary-prevention-our-approach\" class=\"medical medical_review\">Cardiovascular disease risk assessment for primary prevention: Our approach</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-feltys-syndrome\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Felty's syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-rheumatoid-arthritis\" class=\"medical medical_review\">Clinical manifestations of rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-artery-disease-in-rheumatoid-arthritis-implications-for-prevention-and-management\" class=\"medical medical_review\">Coronary artery disease in rheumatoid arthritis: Implications for prevention and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">Diagnostic evaluation of the incidental pulmonary nodule</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">Differential diagnosis and evaluation of multiple pulmonary nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hla-and-other-susceptibility-genes-in-rheumatoid-arthritis\" class=\"medical medical_review\">HLA and other susceptibility genes in rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraarticular-and-soft-tissue-injections-what-agents-to-inject-and-how-frequently\" class=\"medical medical_review\">Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate\" class=\"medical medical_review\">Major side effects of low-dose methotrexate</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurologic-manifestations-of-rheumatoid-arthritis\" class=\"medical medical_review\">Neurologic manifestations of rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-lung-disease-associated-with-rheumatoid-arthritis\" class=\"medical medical_review\">Overview of lung disease associated with rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-systemic-and-nonarticular-manifestations-of-rheumatoid-arthritis\" class=\"medical medical_review\">Overview of the systemic and nonarticular manifestations of rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-cytokines-in-rheumatic-diseases\" class=\"medical medical_review\">Role of cytokines in rheumatic diseases</a></li></ul></div></div>","javascript":null}